Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 4:9:217.
doi: 10.3389/fneur.2018.00217. eCollection 2018.

MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder

Affiliations
Review

MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder

Giordani Rodrigues Dos Passos et al. Front Neurol. .

Abstract

Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been found in some cases diagnosed as seronegative neuromyelitis optica spectrum disorder (NMOSD). MOG-IgG allowed the identification of a subgroup with a clinical course distinct from that of NMOSD patients who are seropositive for aquaporin-4-IgG antibodies. MOG-IgG is associated with a wider clinical phenotype, not limited to NMOSD, with the majority of cases presenting with optic neuritis (ON), encephalitis with brain demyelinating lesions, and/or myelitis. Therefore, we propose the term MOG-IgG-associated Optic Neuritis, Encephalitis, and Myelitis (MONEM). Depending on the clinical characteristics, these patients may currently be diagnosed with NMOSD, acute disseminated encephalomyelitis, pediatric multiple sclerosis, transverse myelitis, or ON. With specific cell-based assays, MOG-IgG is emerging as a potential biomarker of inflammatory disorders of the central nervous system. We review the growing body of evidence on MONEM, focusing on its clinical aspects.

Keywords: encephalitis; myelin oligodendrocyte glycoprotein antibody; myelitis; neuromyelitis optica spectrum disorder; optic neuritis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MOG-IgG-associated optic neuritis, encephalitis, and myelitis (MONEM). The clinical phenotypes associated with MOG-IgG are encompassed under the term MONEM. MONEM is not limited to aquaporin-4-IgG-negative neuromyelitis optica spectrum disorder (NMOSD).
Figure 2
Figure 2
Magnetic resonance imaging (MRI) findings and evolution in a MOG-IgG-positive case fulfilling the diagnosis of neuromyelitis optica spectrum disorder (NMOSD). A young adult presented with recurrent optic neuritis followed by transverse myelitis. Spinal MRI showed a T2-hyperintense, centrally located longitudinally extensive transverse myelitis extending from C4 to C7, with mild cord swelling (A,B). Brain MRI showed a T2/FLAIR-hyperintense lesion on the left superior frontal gyrus (C), with gadolinium enhancement (D). In cell-based assays, aquaporin-4 immunoglobulin G (AQP4-IgG) was negative, and MOG-IgG was positive. Response to immunotherapy was excellent. Follow-up MRI showed complete resolution of the brain and spinal lesions (E,F). This case illustrates that the imaging patterns of MOG-IgG-associated ON, encephalitis, and myelitis (MONEM) often overlap with those of NMOSD, and some cases may even fulfill the 2015 criteria for the diagnosis of NMOSD without AQP4-IgG.

References

    1. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology (2015) 85(2):177–89.10.1212/WNL.0000000000001729 - DOI - PMC - PubMed
    1. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 364:2106–12.10.1016/S0140-6736(04)17551-X - DOI - PubMed
    1. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 202:473–7.10.1084/jem.20050304 - DOI - PMC - PubMed
    1. Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir H, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 80:2194–200.10.1212/WNL.0b013e318296e917 - DOI - PubMed
    1. Sato DK, Callegaro D, Lana-Peixoto MA, Nakashima I, Fujihara K. Seronegative neuromyelitis optica spectrum – the challenges on disease definition and pathogenesis. Arq Neuropsiquiatr (2014) 72:445–50.10.1590/0004-282X20140032 - DOI - PubMed

LinkOut - more resources